About lenvatinib
Multikinase inhibitor
Used for
- Treats thyroid cancer that no longer responds to radioactive iodine.
- Treats certain kidney cancers, usually with another cancer medicine.
- Treats unresectable liver cancer.
- Treats advanced endometrial cancer with pembrolizumab.
Usual adult dose
Usually 24 mg once daily for thyroid or endometrial cancer; 18 mg daily with everolimus for kidney cancer; liver-cancer dosing depends on body weight.
Common side effects
- High blood pressure
- Diarrhea, nausea, or reduced appetite
- Tiredness and weight loss
- Protein in urine
Important warnings
- Can cause severe bleeding, blood clots, or heart problems.
- May impair wound healing; treatment may need pausing around surgery.
- Can cause liver, kidney, or thyroid problems; monitoring is needed.
- Capsules must be swallowed whole or prepared as directed in the official instructions.
Pregnancy
May harm an unborn baby. Avoid pregnancy during treatment and for at least 30 days after the last dose.
Breastfeeding
Do not breastfeed during treatment and for at least one week after the last dose.
Interactions
- Blood-pressure medicines may need adjustment if blood pressure rises.
- Medicines affecting liver enzymes can alter lenvatinib levels.
- Other medicines that prolong the QT interval may increase abnormal-heart-rhythm risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.